# Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct03102424` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03102424](<https://clinicaltrials.gov/study/NCT03102424>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03102424

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT03102424. Randomized; quadruple masking; primary purpose supportive care. Start 2017-04-10 (actual); primary completion 2020-07-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose supportive care
- Phase: Not applicable
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT03102424, source copy `cardio:ctgov-nct03102424-2021-04-01`, retrieved 2026-10-26)
- Started: 2017-04-10 (actual) (ClinicalTrials.gov record NCT03102424, source copy `cardio:ctgov-nct03102424-2021-04-01`, retrieved 2026-10-26)
- Primary completion: 2020-07-15 (actual) (ClinicalTrials.gov record NCT03102424, source copy `cardio:ctgov-nct03102424-2021-04-01`, retrieved 2026-10-26)
- Completion: 2020-07-31 (actual) (ClinicalTrials.gov record NCT03102424, source copy `cardio:ctgov-nct03102424-2021-04-01`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT03102424, source copy `cardio:ctgov-nct03102424-2021-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03102424-2021-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus
- Intervention (Device): Transcutaneous Electrical Nerve Stimulator (DW1330)
- Intervention (Device): Sham DW1330 device
- Lead sponsor: Taiwan Resonant Waves Research Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: a0d1b1e08599ddbea4aaf97d4880a3d3d14e5f08fda9ca62561891065a3b7e2e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
